Michael K Pugsley
Overview
Explore the profile of Michael K Pugsley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaudhary K, Clancy C, Yang P, Pierson J, Goldin A, Koerner J, et al.
Clin Transl Sci
. 2024 Dec;
17(12):e70098.
PMID: 39660576
The human voltage-gated sodium channel Na1.5 (hNa1.5/SCN5A) plays a critical role in the initiation and propagation of action potentials in cardiac myocytes, and its modulation by various drugs has significant...
2.
Bonet-Luz E, Nandi M, Christie M, Doyle J, Pierson J, Pugsley M, et al.
J Pharmacol Toxicol Methods
. 2024 Jul;
129:107546.
PMID: 39069108
The potential for unintended drug induced changes in cardiac contractility is a major concern in medicines development. Whilst direct left ventricular pressure (LVP) measurement is the gold standard for measuring...
3.
Pugsley M, Winters B, Koshman Y, Authier S, Foley C, Hayes E, et al.
J Pharmacol Toxicol Methods
. 2024 Jun;
128:107533.
PMID: 38945308
This editorial prefaces the annual themed issue on safety pharmacology (SP) methods which has been published since 2004 in the Journal of Pharmacological and Toxicological Methods (JPTM). Here we highlight...
4.
Pierson J, Berridge B, Blinova K, Brooks M, Eldridge S, OBrien C, et al.
J Pharmacol Toxicol Methods
. 2024 May;
127:107511.
PMID: 38710237
The Health and Environmental Sciences Institute (HESI) is a nonprofit organization dedicated to resolving global health challenges through collaborative scientific efforts across academia, regulatory authorities and the private sector. Collaborative...
5.
De Alwis D, Foley C, Herman E, Hill A, Hoffmann P, Kanda Y, et al.
J Pharmacol Toxicol Methods
. 2024 Apr;
127:107507.
PMID: 38636673
The Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee designed and created a publicly accessible database with an initial set of 128 pharmacologically defined pharmaceutical agents, many with known...
6.
Boulay E, Troncy E, Jacquemet V, Huang H, Pugsley M, Downey A, et al.
Int J Toxicol
. 2024 Mar;
43(4):357-367.
PMID: 38477622
modeling offers an opportunity to supplement and accelerate cardiac safety testing. With in silico modeling, computational simulation methods are used to predict electrophysiological interactions and pharmacological effects of novel drugs...
7.
Orciani C, Ballesteros C, Troncy E, Berthome C, Bujold K, Bennamoune N, et al.
Int J Toxicol
. 2023 Dec;
43(2):123-133.
PMID: 38063479
When conducting toxicology studies, the interpretation of drug-related neurological clinical signs such as convulsions, myoclonus/myoclonic jerks, tremors, ataxia, and salivation requires an understanding of the spontaneous incidence of those observations...
8.
Pugsley M, Koshman Y, Foley C, Winters B, Authier S, Curtis M
J Pharmacol Toxicol Methods
. 2023 Jul;
123:107300.
PMID: 37524151
This editorial prefaces the annual themed issue on safety pharmacology (SP) methods published since 2004 in the Journal of Pharmacological and Toxicological Methods (JPTM). We highlight here the content derived...
9.
Rossman E, Wisialowski T, Vargas H, Valentin J, Rolf M, Roche B, et al.
J Pharmacol Toxicol Methods
. 2023 May;
123:107270.
PMID: 37164235
The ICH E14/S7B Questions and Answers (Q&As) guideline introduces the concept of a "double negative" nonclinical scenario (negative hERG assay and negative in vivo QTc study) to demonstrate that a...
10.
Vargas H, Rossman E, Wisialowski T, Nichols J, Pugsley M, Roche B, et al.
J Pharmacol Toxicol Methods
. 2023 Mar;
121:107265.
PMID: 36997076
Recent updates and modifications to the clinical ICH E14 and nonclinical ICH S7B guidelines, which both relate to the evaluation of drug-induced delayed repolarization risk, provide an opportunity for nonclinical...